The 2EF mAb was shown to access Trop-2 at cell–cell junctions in breast MCF-7 cancer cells in culture and at deeply seated sites in prostate cancer, that were inaccessible to benchmark anti-Trop-2 mAb. Here, TACSTD2 is linked to prostate carcinoma.